Sai Life Sciences FY26 Revenue at ₹2,192 Cr (up 29%), PAT ₹355 Cr (up 109%)
Sai Life Sciences reported a 29% YoY revenue growth to ₹2,192 crore and a 109% YoY PAT growth to ₹355 crore for FY26. The company plans a Capex of ₹1,100-1,300 crore for FY27 and aims to maintain EBITDA margins of 28-30% over the next 2-3 years.
The announcement details strong financial results, significant Capex plans for future growth, and strategic initiatives that are likely to have a substantial impact on the company's market position and investor confidence.
The company reported significant year-on-year growth in revenue, EBITDA, and PAT, along with strategic expansion plans and positive future outlook, indicating a strong financial performance and positive business trajectory.
Sai Life Sciences Limited has announced its investor presentation for the quarter and year ended March 31, 2026. The company reported strong execution across its business, with revenues increasing by 29% year-on-year to ₹2,192 crore in FY26, up from ₹1,695 crore in FY25. The CDMO segment contributed ₹1,417 crore, a 33% increase, while the CRO segment grew by 24% to ₹775 crore.
EBITDA for FY26 rose by 56% to ₹661 crore from ₹425 crore in FY25, with EBITDA margins expanding by 508 basis points to 30%. Profit After Tax (PAT) saw a significant jump of 109% to ₹355 crore in FY26, compared to ₹170 crore in FY25. The company is doubling down on its capital expenditure (Capex) for FY27, allocating ₹1,100-1,300 crore, aligned with customer demand and strategic growth opportunities.
Looking ahead, Sai Life Sciences is confident in maintaining its EBITDA margin forecast of 28-30% over the next 2-3 years, despite ongoing investments. The company aims for a 15-20% revenue CAGR over the next 3-5 years. The presentation also highlighted strategic initiatives including deepening engagement with large pharma customers, momentum in integrated discovery services, and investments in next-generation technologies like High-Throughput Experimentation and advanced biology platforms. Sustainability remains a focus, with its Bidar manufacturing sites now operating on 100% renewable power.
What to do with a filing like this
Sai Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sai Life Sciences Limited. Read the original for the full detail.